David Tyas

461 total citations
17 papers, 375 citations indexed

About

David Tyas is a scholar working on Economics and Econometrics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, David Tyas has authored 17 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in David Tyas's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Multiple Sclerosis Research Studies (5 papers) and CAR-T cell therapy research (4 papers). David Tyas is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Multiple Sclerosis Research Studies (5 papers) and CAR-T cell therapy research (4 papers). David Tyas collaborates with scholars based in United Kingdom, United States and Australia. David Tyas's co-authors include John Kerrigan, Richard M. Nixon, Nicola S. Russell, Michelle Orme, Danny Liew, Yong Yuan, Edward Gibson, Phil McEwan, A. Juarez-Garcia and Michael Lees and has published in prestigious journals such as Neurology, Drug Discovery Today and Multiple Sclerosis Journal.

In The Last Decade

David Tyas

17 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Tyas United Kingdom 8 212 148 81 49 48 17 375
Sebastian Berg Germany 11 73 0.3× 68 0.5× 126 1.6× 22 0.4× 8 0.2× 43 453
Erin Zagadailov United States 12 76 0.4× 32 0.2× 100 1.2× 24 0.5× 88 1.8× 31 336
Gerd R. Burmester Germany 3 48 0.2× 54 0.4× 22 0.3× 10 0.2× 52 1.1× 4 301
Carin A. Uyl‐de Groot Netherlands 9 47 0.2× 58 0.4× 60 0.7× 25 0.5× 30 0.6× 25 271
K.G. van der Hem Netherlands 8 118 0.6× 12 0.1× 119 1.5× 41 0.8× 43 0.9× 16 268
T. Younis Canada 11 33 0.2× 83 0.6× 184 2.3× 28 0.6× 4 0.1× 32 308
Kashyap Patel United States 10 25 0.1× 56 0.4× 56 0.7× 13 0.3× 25 0.5× 34 288
Anastassia Negrouk Belgium 8 68 0.3× 44 0.3× 74 0.9× 54 1.1× 6 0.1× 23 212
Irène Jiménez France 10 29 0.1× 7 0.0× 100 1.2× 35 0.7× 23 0.5× 34 304
John Waller United Kingdom 10 33 0.2× 76 0.5× 107 1.3× 27 0.6× 77 1.6× 38 415

Countries citing papers authored by David Tyas

Since Specialization
Citations

This map shows the geographic impact of David Tyas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tyas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tyas more than expected).

Fields of papers citing papers by David Tyas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tyas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tyas. The network helps show where David Tyas may publish in the future.

Co-authorship network of co-authors of David Tyas

This figure shows the co-authorship network connecting the top 25 collaborators of David Tyas. A scholar is included among the top collaborators of David Tyas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Tyas. David Tyas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Carroll, Robert, Dara Stein, Delphine Saragoussi, et al.. (2021). Nivolumab in Gastric/Gastroesophageal Junction Cancer: Real-World Data from UK Early Access to Medicines Scheme. Future Oncology. 17(24). 3163–3174. 3 indexed citations
2.
Gibson, Edward, George Dranitsaris, Danny Liew, et al.. (2020). <p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>. ClinicoEconomics and Outcomes Research. Volume 12. 241–252. 3 indexed citations
3.
Kearns, Benjamin, John Stevens, Praveen Thokala, et al.. (2019). A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making. 39(8). 899–909. 36 indexed citations
4.
Wang, Meng, et al.. (2019). Early Access to Medicines Scheme: real-world data collection. Drug Discovery Today. 24(12). 2231–2233. 4 indexed citations
5.
6.
Gibson, Edward, George Dranitsaris, Danny Liew, et al.. (2019). Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Journal of Medical Economics. 22(6). 531–544. 19 indexed citations
7.
Gibson, Edward, George Dranitsaris, Danny Liew, et al.. (2018). Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and Outcomes Research. Volume 10. 139–154. 11 indexed citations
8.
9.
Bullement, Ash, et al.. (2017). Cost Effectiveness of Nivolumab for Patients with Advanced, Previously Treated Renal Cell Carcinoma in Scotland. Value in Health. 20(9). A440–A440. 3 indexed citations
10.
11.
Gibson, Edward, George Dranitsaris, Danny Liew, et al.. (2017). Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. PharmacoEconomics. 35(12). 1257–1270. 54 indexed citations
12.
Roskell, Neil, et al.. (2012). Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Current Medical Research and Opinion. 28(5). 767–780. 31 indexed citations
13.
Karampampa, Korinna, Anders Gustavsson, Carolin Miltenburger, & David Tyas. (2012). Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Multiple Sclerosis Journal. 18(2_suppl). 41–45. 22 indexed citations
14.
Tyas, David, et al.. (2012). Annualized Relapse Rate of First-Line Treatments for Multiple Sclerosis: A Meta-Analysis, Including Indirect Comparisons Versus Fingolimod (P01.136). Neurology. 78(Meeting Abstracts 1). P01.136–P01.136. 1 indexed citations
15.
Kerr, Cicely, Andrew Lloyd, Shehzad Ali, Charles Gore, & David Tyas. (2012). Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. 3(3). e153–e167. 4 indexed citations
16.
Tyas, David, John Kerrigan, Nicola S. Russell, & Richard M. Nixon. (2007). The Distribution of the Cost of Multiple Sclerosis in the UK: How Do Costs Vary by Illness Severity?. Value in Health. 10(5). 386–389. 31 indexed citations
17.
Orme, Michelle, John Kerrigan, David Tyas, Nicola S. Russell, & Richard M. Nixon. (2006). The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK. Value in Health. 10(1). 54–60. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebastian Berg Breakdown of academic impact, for papers by Erin Zagadailov Breakdown of academic impact, for papers by Gerd R. Burmester Breakdown of academic impact, for papers by Carin A. Uyl‐de Groot Breakdown of academic impact, for papers by K.G. van der Hem Breakdown of academic impact, for papers by T. Younis Breakdown of academic impact, for papers by Kashyap Patel Breakdown of academic impact, for papers by Anastassia Negrouk Breakdown of academic impact, for papers by Irène Jiménez Breakdown of academic impact, for papers by John Waller
Rankless by CCL
2026